Cooperative Agreement R43IP001232

This Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $991,832 to Astek Diagnostics Inc., a minority-owned small business, to develop a novel rapid antibiotic susceptibility testing (AST) platform. The project aims to deliver results in under one hour for various specimen types, including urine, cerebrospinal fluid, and wound effluent. This innovative platform is designed to quickly identify...

This $165,507 federal Project Grant award from the U.S. Department of Agriculture's National Institute of Food and Agriculture (NIFA) under the Small Business Innovation Research (SBIR) Program (CFDA 10.212) supports the development and validation of an affordable, handheld quantitative fluorometer and colorimeter system. This technology will enable rapid, field-based enumeration of E. coli and antibiotic-resistant E. coli in agricultural water samples, providing a more accessible alternative to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The goal is to create a microfluidic-enabled technology that can isolate small numbers of bacteria directly from whole blood, identify bacterial pathogens, and evaluate their antibiotic response within 75...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $984,381 to Cobio Diagnostics Inc. in Aurora, Colorado aims to expand a diagnostic tool that enables rapid, direct-from-specimen identification and antimicrobial susceptibility testing of major bloodborne bacterial pathogens. The project will develop a regulatory pathway for FDA clearance, characterize antibodies to expand the test, and validate the expanded tests...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is providing $2,378,837 to the University of Massachusetts to develop novel nanopore- and click-chemistry-based approaches for the rapid, culture-independent detection of sepsis-causing pathogens directly from blood samples. The goal is to enable the early administration of source-directed antibiotics by detecting proteomic biomarkers, such as...

The National Science Foundation (NSF) awarded a $305,000 Project Grant under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) to Giant Biosystems Inc., a small disadvantaged business, to develop a rapid point-of-care antimicrobial susceptibility testing (AST) kit. The project aims to create a microfluidic platform that can provide actionable AST results within 6-9 hours, as opposed to the current 3-5 day turnaround. This will allow physicians to more quickly prescribe...

This $275,000 Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The project, led by Informuta, Inc., a for-profit organization based in New Orleans, LA, will establish the feasibility of leveraging mutational signatures found in bacterial DNA to predict antibiotic...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,170 to Latde Diagnostics Corp., a woman-owned small business, to demonstrate the feasibility of a rapid, equitable antibiotic susceptibility test (AST) for urinary tract infections (UTIs). The goal is to develop a lateral flow assay (LFA) that can detect bacterial growth and determine antibiotic susceptibility...

This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to Bactria Pharmaceuticals LLC is providing $274,937 to develop therapeutic drugs that restore antibiotic sensitivity in bacteria that cause severe healthcare-associated infections. The goal is to combat antimicrobial resistance in gram-negative pathogens through the use of small molecule efflux pump inhibitors (EPIs). The project involves three key activities: cryo-electron microscopy to understand...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,989 to Day Zero Diagnostics Inc. to develop EPIXACT-FMT, a metagenomic, pharmacovigilance assay for microbiota therapeutics safety. The goal of this project is to innovate sample preparation, deep sequencing, and bioinformatic analysis to achieve strain-level resolution of metagenomic donor samples used for...